{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T19:19:00Z","timestamp":1775071140577,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,17]]},"DOI":"10.7759\/cureus.69599","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T18:36:31Z","timestamp":1726598191000},"source":"Crossref","is-referenced-by-count":4,"title":["Serum Interleukin (IL)-6, Lipid Profile, and Association With Disease Severity in Patients With Psoriasis: A Cross-Sectional Study"],"prefix":"10.7759","author":[{"given":"Soumya Ranjan","family":"Sahoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuldip","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharti","family":"Panda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamata","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhusmita","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purnima","family":"Meher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumitra","family":"Bhoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths CE","year":"2007","unstructured":"Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007, 370:263-71. 10.1016\/S0140-6736(07)61128-3","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-018-0781-x","article-title":"Novel concepts in psoriatic arthritis management: can we treat to target?","volume":"20","author":"Tucker LJ","year":"2018","unstructured":"Tucker LJ, Ye W, Coates LC. Novel concepts in psoriatic arthritis management: can we treat to target?. Curr Rheumatol Rep. 2018, 20:71. 10.1007\/s11926-018-0781-x","journal-title":"Curr Rheumatol Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.125472","article-title":"Prevalence and clinical patterns of psoriatic arthritis in Indian patients with psoriasis","volume":"80","author":"Kumar R","year":"2014","unstructured":"Kumar R, Sharma A, Dogra S. Prevalence and clinical patterns of psoriatic arthritis in Indian patients with psoriasis. Indian J Dermatol Venereol Leprol. 2014, 80:15-23. 10.4103\/0378-6323.125472","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-016-1111-9","article-title":"An overview of psoriatic arthritis - epidemiology, clinical features, pathophysiology and novel treatment targets","volume":"128","author":"Kerschbaumer A","year":"2016","unstructured":"Kerschbaumer A, Fenzl KH, Erlacher L, Aletaha D. An overview of psoriatic arthritis - epidemiology, clinical features, pathophysiology and novel treatment targets. Wien Klin Wochenschr. 2016, 128:791-5. 10.1007\/s00508-016-1111-9","journal-title":"Wien Klin Wochenschr"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/535612","article-title":"Lipid disturbances in psoriasis: an update","volume":"2010","author":"Pietrzak A","year":"2010","unstructured":"Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC. Lipid disturbances in psoriasis: an update. Mediators Inflamm. 2010, 2010:535612. 10.1155\/2010\/535612","journal-title":"Mediators Inflamm"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/964069","article-title":"IL-6 as a druggable target in psoriasis: focus on pustular variants","volume":"2014","author":"Saggini A","year":"2014","unstructured":"Saggini A, Chimenti S, Chiricozzi A. IL-6 as a druggable target in psoriasis: focus on pustular variants. J Immunol Res. 2014, 2014:964069. 10.1155\/2014\/964069","journal-title":"J Immunol Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2018.78028","article-title":"Serum concentration of interleukin 6 is related to inflammation and dyslipidemia in patients with psoriasis","volume":"37","author":"Pietrzak A","year":"2020","unstructured":"Pietrzak A, Chabros P, Grywalska E, et al.. Serum concentration of interleukin 6 is related to inflammation and dyslipidemia in patients with psoriasis. Postepy Dermatol Alergol. 2020, 37:41-5. 10.5114\/ada.2018.78028","journal-title":"Postepy Dermatol Alergol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12240","article-title":"Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway","volume":"28","author":"Balato A","year":"2014","unstructured":"Balato A, Schiattarella M, Di Caprio R, Lembo S, Mattii M, Balato N, Ayala F. Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway. J Eur Acad Dermatol Venereol. 2014, 28:1016-24. 10.1111\/jdv.12240","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1155\/MI.2005.273","article-title":"Serum levels of TNF-\u03b1, IFN-\u03b3, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity","volume":"2005","author":"Arican O","year":"2005","unstructured":"Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-\u03b1, IFN-\u03b3, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005, 2005:273-9. 10.1155\/MI.2005.273","journal-title":"Mediators Inflamm"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.16.6367","article-title":"Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes","volume":"86","author":"Grossman RM","year":"1989","unstructured":"Grossman RM, Krueger J, Yourish D, et al.. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A. 1989, 86:6367-71. 10.1073\/pnas.86.16.6367","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12355","article-title":"Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis","volume":"169","author":"Dowlatshahi EA","year":"2013","unstructured":"Dowlatshahi EA, van der Voort EA, Arends LR, Nijsten T. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2013, 169:266-82. 10.1111\/bjd.12355","journal-title":"Br J Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2003.44.6.987","article-title":"Oxidant \/ antioxidant status in patients with psoriasis","volume":"44","author":"Baz K","year":"2003","unstructured":"Baz K, Cimen MY, Kokturk A, et al.. Oxidant \/ antioxidant status in patients with psoriasis. Yonsei Med J. 2003, 44:987-90. 10.3349\/ymj.2003.44.6.987","journal-title":"Yonsei Med J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/s0009-8981(00)00358-2","article-title":"Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease","volume":"303","author":"Rocha-Pereira P","year":"2001","unstructured":"Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta. 2001, 303:33-9. 10.1016\/s0009-8981(00)00358-2","journal-title":"Clin Chim Acta"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283031c99","article-title":"Psoriasis and metabolic disease: epidemiology and pathophysiology","volume":"20","author":"Azfar RS","year":"2008","unstructured":"Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol. 2008, 20:416-22. 10.1097\/BOR.0b013e3283031c99","journal-title":"Curr Opin Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2014.09.008","article-title":"Psoriasis decreases the anti-oxidation and anti-inflammation properties of high-density lipoprotein","volume":"1841","author":"He L","year":"2014","unstructured":"He L, Qin S, Dang L, Song G, Yao S, Yang N, Li Y. Psoriasis decreases the anti-oxidation and anti-inflammation properties of high-density lipoprotein. Biochim Biophys Acta. 2014, 1841:1709-15. 10.1016\/j.bbalip.2014.09.008","journal-title":"Biochim Biophys Acta"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-016-3514-3","article-title":"Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland","volume":"36","author":"Kawalec P","year":"2016","unstructured":"Kawalec P, Malinowski KP, Pilc A. Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland. Rheumatol Int. 2016, 36:1223-30. 10.1007\/s00296-016-3514-3","journal-title":"Rheumatol Int"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2014.2440","article-title":"Cardiovascular risk factors and cardiovascular diseases in patients with moderate to severe psoriasis under systemic treatment. PSO-RISK, descriptive study","volume":"24","author":"Vanaclocha F","year":"2014","unstructured":"Vanaclocha F, Belinch\u00f3n I, S\u00e1nchez-Carazo JL, et al.. Cardiovascular risk factors and cardiovascular diseases in patients with moderate to severe psoriasis under systemic treatment. PSO-RISK, descriptive study. Eur J Dermatol. 2014, 24:662-9. 10.1684\/ejd.2014.2440","journal-title":"Eur J Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2016.59153","article-title":"Presence of selected metabolic syndrome components in patients with psoriasis vulgaris","volume":"33","author":"Uczniak S","year":"2016","unstructured":"Uczniak S, Gerlicz ZA, Koz\u0142owska M, Kaszuba A. Presence of selected metabolic syndrome components in patients with psoriasis vulgaris. Postepy Dermatol Alergol. 2016, 33:114-9. 10.5114\/ada.2016.59153","journal-title":"Postepy Dermatol Alergol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13761","article-title":"Epidemiology and cardiovascular comorbidities in patients with psoriasis: a Korean nationwide population-based cohort study","volume":"44","author":"Oh EH","year":"2017","unstructured":"Oh EH, Ro YS, Kim JE. Epidemiology and cardiovascular comorbidities in patients with psoriasis: a Korean nationwide population-based cohort study. J Dermatol. 2017, 44:621-9. 10.1111\/1346-8138.13761","journal-title":"J Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.11.904","article-title":"Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease","volume":"59","author":"Jones SM","year":"2000","unstructured":"Jones SM, Harris CP, Lloyd J, Stirling CA, Reckless JP, McHugh NJ. Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease. Ann Rheum Dis. 2000, 59:904-9. 10.1136\/ard.59.11.904","journal-title":"Ann Rheum Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10774.x","article-title":"Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study","volume":"166","author":"Li WQ","year":"2012","unstructured":"Li WQ, Han JL, Manson JE, Rimm EB, Rexrode KM, Curhan GC, Qureshi AA. Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study. Br J Dermatol. 2012, 166:811-8. 10.1111\/j.1365-2133.2011.10774.x","journal-title":"Br J Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq105","article-title":"Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis","volume":"49","author":"Chandran V","year":"2010","unstructured":"Chandran V, Cook RJ, Edwin J, et al.. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford). 2010, 49:1399-405. 10.1093\/rheumatology\/keq105","journal-title":"Rheumatology (Oxford)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.55","article-title":"Complexity of the association between psoriasis and comorbidities","volume":"129","author":"Nijsten T","year":"2009","unstructured":"Nijsten T, Wakkee M. Complexity of the association between psoriasis and comorbidities. J Invest Dermatol. 2009, 129:1601-3. 10.1038\/jid.2009.55","journal-title":"J Invest Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2016.1174328","article-title":"Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis","volume":"27","author":"Muramatsu S","year":"2017","unstructured":"Muramatsu S, Kubo R, Nishida E, Morita A. Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis. Mod Rheumatol. 2017, 27:137-41. 10.3109\/14397595.2016.1174328","journal-title":"Mod Rheumatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10005.x","article-title":"Onset of psoriasis following treatment with tocilizumab","volume":"163","author":"Laurent S","year":"2010","unstructured":"Laurent S, Le Parc JM, Cl\u00e9rici T, Br\u00e9ban M, Mah\u00e9 E. Onset of psoriasis following treatment with tocilizumab. Br J Dermatol. 2010, 163:1364-5. 10.1111\/j.1365-2133.2010.10005.x","journal-title":"Br J Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/art.39700","article-title":"The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis","volume":"68","author":"Mease PJ","year":"2016","unstructured":"Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, Banerjee S. The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis. Arthritis Rheumatol. 2016, 68:2163-73. 10.1002\/art.39700","journal-title":"Arthritis Rheumatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2014.16","article-title":"From cytokine to myokine: the emerging role of interleukin-6 in metabolic regulation","volume":"92","author":"Pal M","year":"2014","unstructured":"Pal M, Febbraio MA, Whitham M. From cytokine to myokine: the emerging role of interleukin-6 in metabolic regulation. Immunol Cell Biol. 2014, 92:331-9. 10.1038\/icb.2014.16","journal-title":"Immunol Cell Biol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/256984-serum-interleukin-il-6-lipid-profile-and-association-with-disease-severity-in-patients-with-psoriasis-a-cross-sectional-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T18:36:33Z","timestamp":1726598193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/256984-serum-interleukin-il-6-lipid-profile-and-association-with-disease-severity-in-patients-with-psoriasis-a-cross-sectional-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.69599","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,17]]}}}